EA202092605A1 - Антитела к ил-11ra - Google Patents

Антитела к ил-11ra

Info

Publication number
EA202092605A1
EA202092605A1 EA202092605A EA202092605A EA202092605A1 EA 202092605 A1 EA202092605 A1 EA 202092605A1 EA 202092605 A EA202092605 A EA 202092605A EA 202092605 A EA202092605 A EA 202092605A EA 202092605 A1 EA202092605 A1 EA 202092605A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
antigen
binding
binding molecules
prophylaxis
Prior art date
Application number
EA202092605A
Other languages
English (en)
Inventor
Стюарт Александр Кук
Себастиан Шефер
Original Assignee
Сингапур Хэлс Сервисес Пте. Лтд.
Нэшнл Юниверсити Оф Сингапур
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сингапур Хэлс Сервисес Пте. Лтд., Нэшнл Юниверсити Оф Сингапур, Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Сингапур Хэлс Сервисес Пте. Лтд.
Publication of EA202092605A1 publication Critical patent/EA202092605A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предложены антигенсвязывающие молекулы, способные к связыванию с ИЛ-11R, и способы медицинского лечения и профилактики с применением указанных антигенсвязывающих молекул.
EA202092605A 2018-06-13 2019-06-13 Антитела к ил-11ra EA202092605A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1809700.6A GB201809700D0 (en) 2018-06-13 2018-06-13 IL-11 antibodies
PCT/EP2019/065600 WO2019238884A1 (en) 2018-06-13 2019-06-13 Il-11ra antibodies

Publications (1)

Publication Number Publication Date
EA202092605A1 true EA202092605A1 (ru) 2021-06-01

Family

ID=63042296

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092605A EA202092605A1 (ru) 2018-06-13 2019-06-13 Антитела к ил-11ra

Country Status (24)

Country Link
US (1) US11084878B2 (ru)
EP (1) EP3806959A1 (ru)
JP (1) JP7437325B2 (ru)
KR (1) KR20210031645A (ru)
CN (1) CN113226471A (ru)
AU (1) AU2019286797A1 (ru)
BR (1) BR112020025502A2 (ru)
CA (1) CA3101401A1 (ru)
CL (1) CL2020003218A1 (ru)
CO (1) CO2020015376A2 (ru)
CR (1) CR20210010A (ru)
DO (1) DOP2020000236A (ru)
EA (1) EA202092605A1 (ru)
EC (1) ECSP21001499A (ru)
GB (1) GB201809700D0 (ru)
IL (1) IL279352A (ru)
JO (1) JOP20200300A1 (ru)
MA (1) MA52885A (ru)
MX (1) MX2020013468A (ru)
PE (1) PE20211500A1 (ru)
PH (1) PH12020552229A1 (ru)
SG (1) SG11202011648UA (ru)
TW (1) TW202016140A (ru)
WO (1) WO2019238884A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
KR20190096390A (ko) 2016-12-16 2019-08-19 싱가포르 헬스 서비시즈 피티이 엘티디 Il-11 항체
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
BR112021014105A2 (pt) 2019-01-21 2021-10-13 Singapore Health Services Pte Ltd Agente capaz de inibir a sinalização mediada por interleucina 11, uso do mesmo e método para tratamento ou prevenção da hepatotoxicidade e/ou um distúrbio, doença ou condição associada à hepatotoxicidade
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
EP3962936A1 (en) 2019-05-03 2022-03-09 Singapore Health Services Pte. Ltd. Treatment and prevention of metabolic diseases
GB202009292D0 (en) 2020-06-18 2020-08-05 Singapore Health Serv Pte Ltd Treatment and prevention of disease caused by type IV collagen dysfunction
EP3939999A1 (en) * 2020-07-14 2022-01-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Interleukin 11 receptor alpha subunit (il11ra) neutralizing antibodies and uses thereof
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases
EP4298124A1 (en) 2021-02-26 2024-01-03 Bayer Aktiengesellschaft Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
IL309804A (en) * 2021-07-02 2024-02-01 Laekna Therapeutics Shanghai Co Ltd Depletion of activated hepatic stellate cells (HSCS) and their uses
WO2023006765A1 (en) 2021-07-26 2023-02-02 Boehringer Ingelheim International Gmbh Treatment and prevention of alcoholic liver disease
CN113735975B (zh) * 2021-09-07 2022-08-12 广东东阳光药业有限公司 一种抗il-11r抗体及其应用
WO2023111196A1 (en) 2021-12-16 2023-06-22 Singapore Health Services Pte. Ltd. Treatment and prevention of glomerular disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
PT2953971T (pt) * 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
EP3250609A4 (en) * 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies

Also Published As

Publication number Publication date
CL2020003218A1 (es) 2021-07-30
AU2019286797A1 (en) 2021-01-28
IL279352A (en) 2021-01-31
GB201809700D0 (en) 2018-08-01
MX2020013468A (es) 2021-04-13
SG11202011648UA (en) 2020-12-30
JOP20200300A1 (ar) 2020-11-22
TW202016140A (zh) 2020-05-01
CN113226471A (zh) 2021-08-06
CR20210010A (es) 2021-06-01
BR112020025502A2 (pt) 2021-03-16
WO2019238884A1 (en) 2019-12-19
MA52885A (fr) 2021-04-21
CA3101401A1 (en) 2019-12-19
ECSP21001499A (es) 2021-03-31
DOP2020000236A (es) 2021-10-31
US11084878B2 (en) 2021-08-10
JP2021527086A (ja) 2021-10-11
US20190389957A1 (en) 2019-12-26
JP7437325B2 (ja) 2024-02-22
EP3806959A1 (en) 2021-04-21
US20200377605A9 (en) 2020-12-03
PE20211500A1 (es) 2021-08-11
CO2020015376A2 (es) 2021-04-19
KR20210031645A (ko) 2021-03-22
PH12020552229A1 (en) 2021-06-28

Similar Documents

Publication Publication Date Title
EA202092605A1 (ru) Антитела к ил-11ra
EA202092668A1 (ru) Антитела к ил-11
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201890162A1 (ru) Антитела к cd40 с повышенной агонистической активностью
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201890175A1 (ru) Антитела к cd40
EA201990778A1 (ru) Анти-il-33 антитела и их применение
EA201991546A1 (ru) Антигенсвязывающие белки против нейропилина и способы их применения
EA201592203A1 (ru) Способы лечения таупатии
EA201892716A1 (ru) Антитела к фактору свертывания xi
EA201992460A1 (ru) Антитела-агонисты btla и их применение
EA201992206A1 (ru) Моноклональное антитело к pd-l1
EA202092302A1 (ru) Антитела к trem-1 и их применения
EA202190807A1 (ru) Антитела к синуклеину
EA202191656A1 (ru) Анти-il-36 антитела и способы их применения
EA202190647A1 (ru) Антитела к klrg1
EA202191666A1 (ru) Антитела к il-27 и их применение
EA202191403A1 (ru) Композиция с высокой концентрацией белка
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202190590A1 (ru) Соединения и способы лечения грибковых инфекций
EA202190504A1 (ru) Способы лечения псориаза